Skeletal Muscle Relaxant Classes: A Complete Attorney Guide

James Wong — Founder & Pharmacist, LienScripts | March 29, 2026 | 7 min read

Skeletal muscle relaxants fall into two distinct pharmacological categories — antispasmodics for acute peripheral muscle spasm and antispasticity agents for central nervous system injury. PI attorneys who understand this classification can accurately interpret pharmacy records and connect each prescription to the injury mechanism it documents.

Skeletal muscle relaxants are among the most frequently prescribed drug classes in personal injury cases, but they are not a single category. They divide into antispasmodics that treat peripheral muscle spasm from soft tissue injury and antispasticity agents that treat upper motor neuron dysfunction from spinal cord or brain injury. The distinction matters because the class of muscle relaxant prescribed communicates the treating physician's assessment of injury severity.

• Antispasmodic muscle relaxants (cyclobenzaprine, methocarbamol, metaxalone) target acute musculoskeletal spasm from strains, sprains, and soft tissue injuries
• Antispasticity agents (baclofen, tizanidine, dantrolene) target pathological spasticity from spinal cord injury, TBI, or myelopathy
• Centrally acting agents work in the brain or spinal cord; peripherally acting dantrolene works directly at the muscle fiber
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that documents every muscle relaxant dispensed, tying each to the clinical rationale and injury mechanism
• The specific muscle relaxant class in the pharmacy record is itself evidence of injury type and severity that attorneys should highlight in demand narratives

Antispasmodics vs. Antispasticity: The Core Distinction

The single most important concept for PI attorneys is that antispasmodics and antispasticity agents treat fundamentally different pathologies.

Antispasmodics — cyclobenzaprine (Flexeril), methocarbamol (Robaxin), metaxalone (Skelaxin), orphenadrine, carisoprodol (Soma) — treat the acute, involuntary muscle contraction that follows peripheral musculoskeletal injury. A rear-end collision that produces cervical strain triggers protective muscle spasm as the body splints the injured area. Antispasmodics reduce this spasm through central sedation, anticholinergic effects, or general CNS depression. They are typically prescribed for weeks to a few months after the acute injury.

Antispasticity agents — baclofen, tizanidine (Zanaflex), dantrolene (Dantrium) — treat spasticity, the velocity-dependent increase in muscle tone caused by upper motor neuron damage. Spasticity develops after spinal cord injury, traumatic brain injury, stroke, or severe myelopathy. When these agents appear in a PI pharmacy record, the prescribing physician has determined that the patient's motor dysfunction originates from central nervous system damage — a materially more serious injury finding.

[!KEY] When a PI pharmacy record shows a transition from an antispasmodic (cyclobenzaprine) to an antispasticity agent (baclofen or tizanidine), it documents clinical progression — the treating physician has reclassified the injury from peripheral musculoskeletal spasm to a condition with central nervous system involvement. This transition is a critical evidentiary marker attorneys should flag in the demand narrative.

Centrally Acting Antispasmodics

Cyclobenzaprine (Flexeril)

The most commonly prescribed muscle relaxant in PI cases. Cyclobenzaprine acts centrally in the brainstem to reduce motor neuron activity. It is structurally related to tricyclic antidepressants and carries significant sedation. Standard dosing is 5-10 mg TID, though extended-release 15 mg daily formulations exist. According to James Wong, PharmD, founder of LienScripts, "cyclobenzaprine in the pharmacy record tells you the physician diagnosed acute musculoskeletal spasm — it is the baseline muscle relaxant in PI, and departures from it signal either treatment failure or a different diagnosis."

Methocarbamol (Robaxin)

A centrally acting agent that works through polysynaptic inhibition in the spinal cord and brainstem. Less sedating than cyclobenzaprine for many patients, making it preferred when patients need to remain functional during the day. Available in oral (500 mg, 750 mg tablets) and injectable forms. The injectable form may appear in emergency department records following acute trauma.

Metaxalone (Skelaxin)

Less sedating than cyclobenzaprine with a cleaner side effect profile, but generally considered less potent. Often prescribed when cyclobenzaprine's sedation is intolerable. Its presence in the record may indicate a physician who tried cyclobenzaprine first and switched due to side effects — documenting a second clinical assessment.

Carisoprodol (Soma)

A centrally acting agent metabolized to meprobamate, a Schedule IV controlled substance. Due to abuse potential, carisoprodol is increasingly scrutinized. Defense adjusters may challenge carisoprodol prescriptions as inappropriate. However, when prescribed by a treating physician for documented musculoskeletal spasm, it remains a legitimate clinical choice.

[!TIP] When multiple antispasmodics appear sequentially in the pharmacy record — cyclobenzaprine tried first, then methocarbamol, then metaxalone — it documents treatment resistance that supports the argument that the patient's pain and spasm are severe and difficult to manage, strengthening the damages narrative.

Antispasticity Agents: Central Nervous System Injury Markers

Baclofen

A GABA-B receptor agonist that acts at the spinal cord to suppress the disinhibited motor neuron firing that drives spasticity. Baclofen's presence in a PI record is a high-severity injury signal — the treating physician has determined the patient has upper motor neuron dysfunction. Baclofen carries serious discontinuation risks including seizures and hallucinations, supporting the argument for continuous pharmacy lien coverage.

Tizanidine (Zanaflex)

An alpha-2 adrenergic agonist that reduces spasticity by inhibiting excitatory neurotransmitter release at the spinal level. Tizanidine occupies a middle ground — it is FDA-approved for spasticity but is also frequently prescribed off-label for severe, refractory muscle spasm in cases with a neurological component that does not meet the full diagnostic criteria for spasticity. Its presence suggests the physician assessed a neurological contribution to the patient's motor dysfunction.

Dantrolene (Dantrium)

The only peripherally acting muscle relaxant. Dantrolene works directly at the muscle fiber by blocking calcium release from the sarcoplasmic reticulum, reducing the force of muscle contraction. It is reserved for severe spasticity, particularly from spinal cord injury and TBI, and carries hepatotoxicity risk requiring liver function monitoring. Dantrolene in a PI pharmacy record documents a severe spasticity case with active pharmacological monitoring.

What the Muscle Relaxant Class Tells the Adjuster

Insurance adjusters and defense attorneys categorize muscle relaxants as generic soft-tissue medications. This is an oversimplification that attorneys should challenge.

[!KEY] Defense adjusters who lump all muscle relaxants together as "soft tissue medications" are ignoring the pharmacological distinction between antispasmodics and antispasticity agents. Attorneys should educate opposing counsel that baclofen or dantrolene in the record documents central nervous system injury, not routine muscle soreness.

Duration of Treatment as Evidence

Treatment duration with muscle relaxants directly correlates with injury severity and is admissible evidence in the damages analysis.

Antispasmodic prescriptions typically run 2-8 weeks for mild soft tissue injuries. When cyclobenzaprine prescriptions extend beyond 3 months, it documents persistent spasm that exceeds the expected healing timeline — supporting arguments for chronic injury or complications.

Antispasticity agents are often prescribed for months to years, sometimes indefinitely in SCI and TBI cases. Long-duration baclofen or tizanidine prescribing establishes that the neurological injury has not resolved and requires ongoing pharmacological management.

LienScripts captures the complete fill history for every muscle relaxant dispensed under lien, and the MERIT report presents this chronology in a format designed for demand package inclusion.

Pharmacy Lien Coverage Across All Classes

All skeletal muscle relaxants — whether antispasmodic or antispasticity, generic or brand, oral or injectable — are covered under pharmacy lien when prescribed by a treating physician for injuries attributable to the incident. As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "the pharmacist reviews every muscle relaxant prescription against the clinical record to confirm the connection to the documented injuries, and that clinical review is documented in the dispensing record."

[!TIP] When preparing a demand package involving multiple muscle relaxants, organize them chronologically to show the treatment progression — from initial antispasmodic for acute spasm through any escalation to antispasticity agents. This narrative arc demonstrates injury severity evolution and supports the argument for higher damages.

Related Resources

• Cyclobenzaprine vs. Tizanidine: Muscle Relaxant Comparison for PI Cases
• Baclofen for Spasticity in Personal Injury Cases
• Spinal Cord Injury Medications and Long-Term Pharmacy Lien
• Demand Package Pharmacy Records